title: Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.
abstract: A licensed vaccine against Francisella tularensis is currently not available. Two Francisella tularensis subsp. novicida (herein referred to by its earlier name, Francisella novicida) attenuated strains, the ΔiglB and ΔfopC strains, have previously been evaluated as potential vaccine candidates against pneumonic tularemia in experimental animals. F. novicida ΔiglB, a Francisella pathogenicity island (FPI) mutant, is deficient in phagosomal escape and intracellular growth, whereas F. novicida ΔfopC, lacking the outer membrane lipoprotein FopC, which is required for evasion of gamma interferon (IFN-γ)-mediated signaling, is able to escape and replicate in the cytosol. To dissect the difference in protective immune mechanisms conferred by these two vaccine strains, we examined the efficacy of the F. novicida ΔiglB and ΔfopC mutants against pulmonary live-vaccine-strain (LVS) challenge and found that both strains provided comparable protection in wild-type, major histocompatibility complex class I (MHC I) knockout, and MHC II knockout mice. However, F. novicida ΔfopC-vaccinated but not F. novicida ΔiglB-vaccinated perforin-deficient mice were more susceptible and exhibited greater bacterial burdens than similarly vaccinated wild-type mice. Moreover, perforin produced by natural killer (NK) cells and release of granzyme contributed to inhibition of LVS replication within macrophages. This NK cell-mediated LVS inhibition was enhanced with anti-F. novicida ΔfopC immune serum, suggesting antibody-dependent cell-mediated cytotoxicity (ADCC) in F. novicida ΔfopC-mediated protection. Overall, this study provides additional immunological insight into the basis for protection conferred by live attenuated F. novicida strains with different phenotypes and supports further investigation of this organism as a vaccine platform for tularemia.
authors.affiliation: South Texas Center for Emerging Infectious Diseases and Center of Excellence in Infection Genomics, University of Texas at San Antonio, San Antonio, Texas, USA.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Sanapala
authors.forename: Jieh-Juen
authors.initials: JJ
authors.lastname: Yu
authors.forename: Ashlesh K
authors.initials: AK
authors.lastname: Murthy
authors.forename: Weidang
authors.initials: W
authors.lastname: Li
authors.forename: M Neal
authors.initials: MN
authors.lastname: Guentzel
authors.forename: James P
authors.initials: JP
authors.lastname: Chambers
authors.forename: Karl E
authors.initials: KE
authors.lastname: Klose
authors.forename: Bernard P
authors.initials: BP
authors.lastname: Arulanandam
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000378:metabolism; D001428:Bacterial Vaccines; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology; D002478:Cells, Cultured; D018920:Coculture Techniques; D005604:Francisella tularensis / Q000276:immunology*; D005786:Gene Expression Regulation; D005805:Genes, MHC Class I / Q000235:genetics / Q000502:physiology; D005802:Genes, MHC Class II / Q000235:genetics / Q000502:physiology; D053804:Granzymes / Q000235:genetics / Q000378:metabolism*; D008264:Macrophages / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D054353:Perforin / Q000235:genetics / Q000378:metabolism*; D014406:Tularemia / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination; D014613:Vaccines, Attenuated
chemical_list: D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D054353:Perforin; D053804:Granzymes